Claim Your New User Special: Get your second month free ▶ Second Month Free

Serving leading biopharmaceutical companies globally:

Merck
McKinsey
Dow
AstraZeneca
Johnson and Johnson
Medtronic

Last Updated: May 28, 2022

DEPO-SUBQ PROVERA 104 Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard

Which patents cover Depo-subq Provera 104, and what generic alternatives are available?

Depo-subq Provera 104 is a drug marketed by Pfizer and is included in one NDA.

The generic ingredient in DEPO-SUBQ PROVERA 104 is medroxyprogesterone acetate. There are twenty drug master file entries for this compound. Twenty-four suppliers are listed for this compound. Additional details are available on the medroxyprogesterone acetate profile page.

Drug patent expirations by year for DEPO-SUBQ PROVERA 104
Recent Clinical Trials for DEPO-SUBQ PROVERA 104

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
University of Missouri, Kansas CityPhase 3
Teva Branded Pharmaceutical Products R&D, Inc.Phase 1
University of California, San DiegoEarly Phase 1

See all DEPO-SUBQ PROVERA 104 clinical trials

Pharmacology for DEPO-SUBQ PROVERA 104
Drug Class Progestin

US Patents and Regulatory Information for DEPO-SUBQ PROVERA 104

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Pfizer DEPO-SUBQ PROVERA 104 medroxyprogesterone acetate INJECTABLE;SUBCUTANEOUS 021583-001 Dec 17, 2004 RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for DEPO-SUBQ PROVERA 104

See the table below for patents covering DEPO-SUBQ PROVERA 104 around the world.

Country Patent Number Title Estimated Expiration
Czech Republic 20023750 See Plans and Pricing
Denmark 1282402 See Plans and Pricing
World Intellectual Property Organization (WIPO) 0187266 See Plans and Pricing
South Korea 20030020280 See Plans and Pricing
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for DEPO-SUBQ PROVERA 104

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0113964 97C0037 Belgium See Plans and Pricing PRODUCT NAME: OESTROGENES EQUINS CONJUGUES; ACETATE DE MEDROXYPROGESTERONE; NAT. REGISTRATION NO/DATE: NL 19569 19950301; FIRST REGISTRATION: CH - 52647 01 010 19940826
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Harvard Business School
Boehringer Ingelheim
Colorcon
Merck
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.